Grattan 1997 (H).

Methods	DESIGN Within‐patient Delivery unclear ALLOCATION Random Method of randomisation: pre‐determined randomisation schedule Concealment: unclear BLINDING Open WITHDRAWAL/DROPOUT Described
Participants	N: 25 Treatment duration: 4 wks; FU: 16 weeks LF: not reported BC: yes Age: 44.0 (range = 20 to 72) Gender (per cent men): 52.0%) Severity: BSA = 16.1% (range = 4.1% to 47.8%); TSS (target sites) = 6.3 (range = NR) INCLUSION CRITERIA Bilateral stable chronic plaque psoriasis Adult Hospitalised for routine dithranol treatment EXCLUSION CRITERIA Intolerance of dithranol Unstable or pustular psoriasis Calcium metabolism disorders Systemic psoriasis treatment Recent UVB or PUVA therapy Pregnancy or lactation
Interventions	Calcipotriol ointment 0.005% BD (C) Dithranol in aqueous gel (dose titration 0.1% to 2.0%) BD (D)
Outcomes	Severity (erythema; scaling; palpability) Total Severity Score Patient assessment of irritation (VAS) Investigator assessment of skin staining (none, mild, moderate, or severe)
Notes	There was inpatient treatment to ensure high level of compliance. Dermal Laboratories sponsored the trial.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	High risk	The trial was open.
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Unclear risk	The trial did not report this.
Baseline assessments	Low risk	These were reported.
Baseline comparability demonstrated	Low risk	This was demonstrated.